Tell us who you want to see featured on the list – and why, using the link below. We are counting on you to nominate your collaborators, colleagues and peers.
Nominations are now open for The Medicine Maker 2020 Power List.
Viral contamination can have devastating effects. But innovations upstream can help prevent that.
ADCs have suffered a few setbacks over the years, but interest in their therapeutic potential – particularly against cancer – remains high.
Innovation in glass continues to be a key enabler for allowing pharma manufacturers to make better, safer products for patients.
Serena Fries Smith,
Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.
Gene is in charge of seed train duty! But the reality doesn’t quite live up to his expectations…
What lies ahead for Gene and Eva in 2019? Cell and gene therapies!
It’s time for pharma to leave behind the highly energy-dependent and inflexible processes of the 20th century. Let’s “biologicalize” manufacturing.
The stem cell industry needs to embrace bioprocess control systems to develop consistent, high quality, and commercially viable bioprocesses.
Serena Fries Smith
Intensifying or simplifying your bioprocess can mean more product, shorter manufacturing times, or lower costs.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.